## Darron R Brown

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/424742/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women. Tumour Virus Research, 2022, 13, 200236.	3.8	3
2	A community-based approach to cervical cancer prevention in western Kenya: An AMPATH feasibility project. SAGE Open Medicine, 2022, 10, 205031212211021.	1.8	0
3	Human Papillomavirus Oral- and Sero- Positivity in Fanconi Anemia. Cancers, 2021, 13, 1368.	3.7	3
4	Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines. Vaccine, 2021, 39, 2214-2223.	3.8	7
5	Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine, 2021, 39, 2224-2236.	3.8	25
6	Longer duration of anti-retroviral therapy is associated with decreased risk of human papillomaviruses detection in Kenyan women living with HIV. International Journal of STD and AIDS, 2021, 32, 1212-1220.	1.1	6
7	Detection of types of HPV among HIVâ€infected and HIVâ€uninfected Kenyan women undergoing cryotherapy or loop electrosurgical excision procedure. International Journal of Gynecology and Obstetrics, 2020, 151, 279-286.	2.3	4
8	Persistence of oncogenic and non-oncogenic human papillomavirus is associated with human immunodeficiency virus infection in Kenyan women. SAGE Open Medicine, 2020, 8, 205031212094513.	1.8	7
9	Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Research (Amsterdam, Netherlands), 2020, 10, 100202.	4.5	27
10	Detection and Concentration of Plasma Aflatoxin Is Associated With Detection of Oncogenic Human Papillomavirus in Kenyan Women. Open Forum Infectious Diseases, 2019, 6, .	0.9	11
11	Knowledge of Cervical Cancer and Acceptability of Prevention Strategies Among Human Papillomavirus-Vaccinated and Human Papillomavirus-Unvaccinated Adolescent Women in Eldoret, Kenya. BioResearch Open Access, 2019, 8, 139-145.	2.6	15
12	Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. Vaccine, 2019, 37, 6832-6841.	3.8	6
13	Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics, 2019, 143, .	2.1	45
14	A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women. BMC Infectious Diseases, 2019, 19, 352.	2.9	19
15	Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. Human Vaccines and Immunotherapeutics, 2019, 15, 1962-1969.	3.3	27
16	Association of detection of aflatoxin in plasma of Kenyan women with increased detection of oncogenic HPV Journal of Clinical Oncology, 2019, 37, 5530-5530.	1.6	1
17	Comparison of HPV detection in HIV-infected and HIV-uninfected Kenyan women with or without cervical dysplasia Journal of Clinical Oncology, 2019, 37, e17015-e17015.	1.6	0
18	Redetection of human papillomavirus type 16 infections of the cervix in mid-adult life. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 75-79.	4.5	12

DARRON R BROWN

#	Article	IF	CITATIONS
19	AMPATH Oncology: Baseline HPV detection in Kenyan women enrolled in a longitudinal study of modifiable factors predicting cervical dysplasia Journal of Clinical Oncology, 2018, 36, 5533-5533.	1.6	0
20	Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clinical Infectious Diseases, 2016, 63, 519-527.	5.8	360
21	Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. Clinical Infectious Diseases, 2016, 63, 1281-1287.	5.8	44
22	Invasive cervical cancers in the United States, Botswana and Kenya: HPV type distribution and health policy implications. Infectious Agents and Cancer, 2016, 11, 56.	2.6	13
23	Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 61-69.	4.5	30
24	Clarification on the Impact of Cervarix Vaccination on Human Papillomavirus Infection and Cervical Cancer in the United Kingdom. Human Vaccines and Immunotherapeutics, 2016, 12, 00-00.	3.3	2
25	Episodic detection of human papillomavirus within a longitudinal cohort of young women. Journal of Medical Virology, 2015, 87, 2122-2129.	5.0	29
26	Oral Human Papillomavirus Is Common in Individuals with Fanconi Anemia. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 864-872.	2.5	23
27	DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women. Sexually Transmitted Infections, 2014, 90, 64-69.	1.9	9
28	Invasive cervical cancers from women living in the United States or Botswana: differences in human papillomavirus type distribution. Infectious Agents and Cancer, 2014, 9, 22.	2.6	11
29	Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. Vaccine, 2014, 32, 5880-5887.	3.8	38
30	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1997-2008.	2.5	137
31	Association of Chlamydia trachomatis Infection With Redetection of Human Papillomavirus After Apparent Clearance. Journal of Infectious Diseases, 2013, 208, 1416-1421.	4.0	27
32	Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women. Journal of Medical Virology, 2013, 85, 1786-1793.	5.0	16
33	Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction. Pediatrics, 2012, 130, e249-e256.	2.1	111
34	Prevalence of Human Papillomavirus Infection in Young Women Receiving the First Quadrivalent Vaccine Dose. JAMA Pediatrics, 2012, 166, 774.	3.0	14
35	Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 287-296.	2.5	98
36	The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay. Hum Vaccin, 2011, 7, 230-238.	2.4	97

DARRON R BROWN

#	Article	IF	CITATIONS
37	Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1585-1594.	2.5	73
38	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virusâ€Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPVâ€Naive Women Aged 16–26 Years. Journal of Infectious Diseases, 2009, 199, 926-935.	4.0	528
39	Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin, 2009, 5, 696-704.	2.4	184
40	Prevalence and Persistence of Cervical Human Papillomavirus Infection in HIV-Positive Women Initiating Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 274-282.	2.1	54
41	The human papillomavirus type 11 E1^E4 protein is a transglutaminase 3 substrate and induces abnormalities of the cornified cell envelope. Virology, 2006, 345, 290-298.	2.4	23
42	Association of Condom Use, Sexual Behaviors, and Sexually Transmitted Infections With the Duration of Cenital Human Papillomavirus Infection Among Adolescent Women. JAMA Pediatrics, 2006, 160, 151.	3.0	98
43	A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent Women. Journal of Infectious Diseases, 2005, 191, 182-192.	4.0	364
44	Intracellular Expression Patterns of the Human Papillomavirus Type 59 E1^E4 Protein in COS Cells, Keratinocytes, and Genital Epithelium. Intervirology, 2004, 47, 321-327.	2.8	4
45	Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine, 2004, 22, 2936-2942.	3.8	77
46	Distribution of Human Papillomavirus Types in Cervicovaginal Washings From Women Evaluated in a Sexually Transmitted Diseases Clinic. Sexually Transmitted Diseases, 2002, 29, 763-768.	1.7	27
47	Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. Journal of Medical Virology, 2001, 64, 550-559.	5.0	97
48	High-grade dysplasia in genital warts from two patients infected with the human immunodeficiency virus. Journal of Medical Virology, 1998, 54, 69-73.	5.0	17
49	Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration. , 1997, 53, 185-188.		33
50	Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle lgG concentration. , 1997, 53, 185.		1
51	Temporal and histologic relationships of proliferating cell nuclear antigen and human papillomavirus type 11 in the mouse xenograft system. , 1996, 48, 108-113.		4
52	Detection of human papillomavirus L1 protein in condylomata acuminata from adults with defects in cell-mediated immunity. Journal of Medical Virology, 1993, 41, 79-84.	5.0	4
53	Detection of human papillomavirus types 6 and 11 E4 gene products in condylomata acuminatum. Journal of Medical Virology, 1991, 34, 20-28.	5.0	18